Lipid Peroxidation Products in the Blood Plasma of Patients with Parkinson’s Disease as Possible Biomarkers of Different Stages of the Disease

Fedorova, T.N.; Logvinenkoa, A.A.; Poleshchuka, V.V.; Muzychuka, O.A.; Shabalinaa, A.A.; Illarioshkin, S.N.

Авторы: Fedorova T.N., Logvinenkoa A.A., Poleshchuka V.V., Muzychuka O.A., Shabalinaa A.A., Illarioshkin S.N.
Журнал: Neurochemical Journal
Том: 13
Номер: 4
Год издания: 2019
Издательство: Maik Nauka/Interperiodica Publishing
Местоположение издательства: Russian Federation
Первая страница: 391
Последняя страница: 395
DOI: 10.1134/S1819712419040020
Аннотация: LAbstract—Oxidative stress (OS) plays a significant role in the pathogenesis of Parkinson’s disease (PD) andis accompanied by the development of free radical reactions of lipid peroxidation. The growth of highly reac-tive products of oxidative metabolism of polyunsaturated fatty acids (PUFAs) leads to dysfunction and thesubsequent death of dopaminergic neurons and contributes to the emergence and progression of PD. Thispaper assesses the prognostic significance of lipid peroxidation (LPO) products determined in the blood ofpatients with PD as possible biomarkers of various stages of the disease. The content of lipid hydroperoxides(LH), malondialdehyde (MDA), and 4-hydroxynonenals (4-HNE) was determined in the peripheral bloodof 240 patients at stages 1–4 of the disease according to the Hoehn and Yahr scale. For all examined patients,regardless of the stage of the disease (stages 2–4), an increase in the level of lipid hydroperoxides by 20% wasobserved, on average. Elevated levels of MDA were registered in patients with a higher disease severity whowere at the advanced stages of the disease (stages 3 and 4). For patients at stages 1 and 2 of the disease thecontent of MDA remained within normal levels. The content of 4-HNE increased in patients at stages 2, 3,and 4 of the disease proportionally to the severity of the disease. The most pronounced increase in the contentof 4-HNE was detected in patients at the advanced stages of the disease (stages 3 and 4). In patients at thesecond, earlier stage of the disease, the value of this parameter was 34% lower than that in patients at theadvanced stages. In patients at the first stage of the disease, all measured parameters of LPO were comparableto control values and therefore could not play a significant diagnostic biomarker role. An important aspect ofthis study is that some LPO markers (LH and 4-HNE) are associated with both early and late stages of thedisease, while the content of MDA increased at the advanced stages. Therefore, MDA and 4-HNE may havea high prognostic value, reflecting the severity of the disease. The most sensitive and specific indicator ofLPO is 4-HNE, since its content increases proportionally to the severity of the disease (stage 2 < stage 3 <stage 4). The results we obtained are important for the development of complex neuroprotective approachesto the treatment of this disease, which can prevent the selective death of nervous tissue in PD and delay thedevelopment of the neurodegenerative process
Добавил в систему: Полещук Всеволод Владимирович

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ЦЭМИ РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ЦЭМИ РАН

Lipid Peroxidation Products in the Blood Plasma of Patients with Parkinson’s Disease as Possible Biomarkers of Different Stages of the Diseaseстатья

Прикрепленные файлы